Showing 1211-1220 of 1560 results for "".
- How is Night Vision Maintained During Retinal Disease? Research Provides New Insighthttps://modernod.com/news/how-is-night-vision-maintained-during-retinal-disease-research-provides-new-insight/2478325/New research from a team including scientists from the John A. Moran Eye Center at the University of Utah provides insight on how people with retinal degenerative disease can maintain their night vision for a relatively long period of time. A
- BlephEx Asserts Claims of Patent Infringement and False Advertising Against Myco Industrieshttps://modernod.com/news/blephex-asserts-claims-of-patent-infringement-and-false-advertising-against-myco-industries/2476700/BlephEx, creator of the BlephEx device and eyelid cleaning procedure, announced that it has asserted claims of willful patent infringement and false advertising against Myco Industries and John R
- Aldeyra Therapeutics to Present Phase 2b Dry Eye Disease Results at ARVOhttps://modernod.com/news/aldeyra-therapeutics-to-present-phase-2b-dry-eye-disease-results-at-arvo/2476456/Aldeyra Therapeutics announced that John Sheppard, MD, Professor of Ophthalmology at Eastern Virginia Medical School, will present results of the phase 2b clinical trial of topical reproxalap in dry eye disea
- NIH Study: Experimental Drug May Help Treat Condition May Help Treat Diabetic Retinopathyhttps://modernod.com/news/nih-study-experimental-drug-may-help-treat-condition-may-help-treat-diabetic-retinopathy/2482805/A new National Institutes of Health (NIH)-funded study led by scientists at the Wilmer Eye Institute, Johns Hopkins Medicine researchers determined that low blood sugar, or hypoglycemia, may promote a breakdown of the blood-retinal barrier, an important boundary that regulates the flow of nu
- Staar Opens New Experience Center to Meet Growing Surgeon Demandhttps://modernod.com/news/staar-opens-new-experience-center-to-meet-growing-surgeon-demand/2482452/Staar Surgical announced the expansion of its Staar Surgical Experience Center near John Wayne Airport (SNA) in Lake Forest, California. The new center aims to provide comprehensive, hands-on training and education in lens-based vision correction. Staar says the 
- jCyte Announces Pre-Phase 3 Type B Meeting with FDA; Outlines Plans to Start Pivotal Trial of jCell for RPhttps://modernod.com/news/jcyte-announces-pre-phase-3-type-b-meeting-with-fda-outlines-plans-to-start-pivotal-trial-of-jcell-for-rp/2482126/jCyte announced the successful outcome of its pre-phase 3 Type B meeting with the FDA held on January 16, 2024. Additionally, the company is gearing up to commence its pivotal US trial for jCell for retinitis pigmentosa (RP) in the second half of 2024. John Sholar, Chief Executive
- Bausch + Lomb Announces Leadership Changeshttps://modernod.com/news/bausch-lomb-announces-leadership-changes/2481644/Bausch + Lomb announced a reshaping of its executive leadership team, including the elevation of all business unit heads. Luc Bonnefoy, senior vice president (SVP), Surgical; John Ferris, SVP, Consumer; and Yang Yang, SVP, Vision Care; will join the executive management team of the comp
- Experimental Drug Inhibits or Prevents Diabetic Eye Disease in Wilmer Eye Institute Studyhttps://modernod.com/news/experimental-drug-inhibits-or-prevents-diabetic-eye-disease-in-wilmer-eye-institute-study/2481638/Researchers at Wilmer Eye Institute, Johns Hopkins Medicine say they have evidence that an experimental drug may prevent or slow vision loss in people with diabetes. The results are from a study that used mouse as well as human retinal organoids and eye cell lines. The team focused on m
- AI Used to Advance Drug Delivery System for Glaucoma and Other Chronic Diseaseshttps://modernod.com/news/ai-used-to-advance-drug-delivery-system-for-glaucoma-and-other-chronic-diseases/2481636/Researchers from Wilmer Eye Institute, Johns Hopkins Medicine say they have used artificial intelligence models and machine-learning algorithms to successfully predict which components of amino acids that make up therapeutic proteins are most likely to safely deliver therapeutic drugs to animal e
- eSight Names New Senior Leadershiphttps://modernod.com/news/esight-names-new-senior-leadership/2481562/eSight announced the selection of John Tushar as the new Chairman of the Board; Aaron Tutwiler as the new CEO; and Roland Mattern as Director of Sales and Marketing. In these new roles, the three senior leaders will drive forward the execution of the company’s long-term